1-甲基环丙烷-1-甲酸乙酯 | 71441-76-4

• 物质功能分类: 化学试剂 - 有机试剂 - 酯类
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 1-甲基环丙烷-1-甲酸乙酯
• 英文名称: 1-Methylcyclopropancarbonsaeure-ethylester
• 英文别名: ethyl 1-methylcyclopropane-1-carboxylate；1-Methyl-cyclopropyl-carbonsaeure-ethylester；1-methylcyclopropanecarboxylic acid ethyl ester；ethyl 1-methylcyclopropane-carboxylate；1-Methyl-cyclopropancarbonsaeure-aethylester；ethyl 1-methyl-1-cyclopropanecarboxylate；1-methylcyclopropanoic acid ethyl ester；ethyl 1-methylcyclopropyl carboxylate；Ethyl 1-methylcyclopropanecarboxylate
• CAS: 71441-76-4
• 化学式: C₇H₁₂O₂
• 分子量: 128.171
• InChiKey: IZPYNZLFBUQGCZ-UHFFFAOYSA-N

物化性质

• 沸点：
  136°C
• 密度：
  0,918 g/cm3
• 闪点：
  30°C

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  9
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险等级：
  3.2
• 危险品标志：
  F
• 安全说明：
  S16
• 危险类别码：
  R10
• 海关编码：
  2916209090
• 包装等级：
  III
• 危险类别：
  3.2
• 危险品运输编号：
  UN 1993
• 危险性防范说明：
  P264,P270,P301+P312,P330
• 危险性描述：
  H302

SDS

Name:	Ethyl 1-methylcyclopropane-1-carboxylate 97% Material Safety Data Sheet
Synonym:
CAS:	71441-76-4

Section 1 - Chemical Product MSDS Name:Ethyl 1-methylcyclopropane-1-carboxylate 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
71441-76-4	Ethyl 1-methylcyclopropane-1-carboxyla	97%	275-461-6

Hazard Symbols: None Listed.
Risk Phrases: 10

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Flammable.Flammable liquid.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. Flammable liquid and vapor.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Remove all sources of ignition. Use a spark-proof tool.

---

Section 7 - HANDLING and STORAGE
Handling:
Use spark-proof tools and explosion proof equipment. Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Keep away from sources of ignition. Store in a cool, dry place.
Store in a tightly closed container. Flammables-area.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate general or local explosion-proof ventilation to keep airborne levels to acceptable levels.
Exposure Limits CAS# 71441-76-4: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Liquid
Color: colorless
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: 136 deg C @760mmHg
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: 30 deg C ( 86.00 deg F)
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density: 0.918
Molecular Formula: C7H12O2
Molecular Weight: 128

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials, ignition sources.
Incompatibilities with Other Materials:
Strong oxidizing agents, acids, bases.
Hazardous Decomposition Products:
Carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 71441-76-4 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
Ethyl 1-methylcyclopropane-1-carboxylate - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: FLAMMABLE LIQUID, N.O.S.*
Hazard Class: 3
UN Number: 1993
Packing Group: III
IMO
Shipping Name: FLAMMABLE LIQUID, N.O.S.
Hazard Class: 3
UN Number: 1993
Packing Group: III
RID/ADR
Shipping Name: FLAMMABLE LIQUID, N.O.S.
Hazard Class: 3
UN Number: 1993
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
R 10 Flammable.
Safety Phrases:
S 16 Keep away from sources of ignition - No
smoking.
WGK (Water Danger/Protection)
CAS# 71441-76-4: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 71441-76-4 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 71441-76-4 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-甲基环丙烷-1-甲酸乙酯 在 sodium hydroxide 、 盐酸 作用下， 以 甲醇 、 水 为溶剂， 生成 1-甲基环丙烷-1-羧酸
  参考文献：
  名称：

  β-Arylation of Carboxamides via Iron-Catalyzed C(sp³)–H Bond Activation

  摘要：

  A 2,2-disubstituted propionamide bearing an 8-aminoquinolinyl group as the amide moiety can be arylated at the beta-methyl position with an organozinc reagent in the presence of an organic oxidant, a catalytic amount of an iron salt, and a biphosphine ligand at 50 degrees C. Various features of selectivity and reactivity suggest the formation of an organometallic intermediate via rate-determining C-H bond cleavage rather than a free-radical-type reaction pathway.

  DOI：

  10.1021/ja402806f
• 作为产物：
  描述：

  2,4-Dichloro-2-methyl-butyric acid ethyl ester 在 四乙基对甲苯磺酸铵 作用下， 以 二甲基亚砜 为溶剂， 以73%的产率得到1-甲基环丙烷-1-甲酸乙酯
  参考文献：
  名称：

  通过铜（I）催化的光化学加成反应，然后通过电还原脱卤反应，由缺电子的烯烃和二氯甲烷合成环丙烷衍生物

  摘要：

  缺电子的烯烃与二氯甲烷的CuCl催化光化学反应生成1,3-二氯化合物，然后通过电化学还原得到环丙烷衍生物。

  DOI：

  10.1039/c39830001446

文献信息

• 3-oxadiazolyl-1,6-naphthyridine derivatives
  申请人：Dainippon Pharmaceutical Co., Ltd.

  公开号：US05367078A1

  公开（公告）日：1994-11-22

  3-Oxadiazolyl-5,6,7,8-tetrahydro-1,6-naphthyridine derivative of the formula (I): ##STR1## wherein Het is an oxadiazole ring, R.sub.1 is hydrogen atom, an acyl group, a lower alkyl group or a group of the formula: --CH.sub.2 R.sub.1 ' (in which R.sub.1 ' is a cyclo-lower alkyl group, a lower alkenyl group, a lower alkynyl group, benzyl group, aryl group or a heteroaromatic groups), R.sub.2 is a lower alkyl group, a cyclo-lower alkyl group, a lower alkenyl group, a lower alkynyl group, aryl group, a heteroaromatic group, a halogeno-lower alkyl group, a lower alkoxy-lower alkyl group, a lower alkoxy group, a lower alkenyloxy group, a phenoxy group, or a lower alkylthio group, or a pharmaceutically acceptable acid addition salt thereof, which are useful as benzodiazedine receptor agonist.

  3-氧代唑基-5,6,7,8-四氢-1,6-萘啶衍生物的化学式（I）：##STR1## 其中Het是氧代唑环，R.sub.1是氢原子，酰基，较低的烷基基团或化学式的基团：--CH.sub.2 R.sub.1'（其中R.sub.1'是环状较低烷基基团，较低烯基基团，较低炔基团，苄基团，芳基或杂芳基团），R.sub.2是较低的烷基基团，环状较低烷基基团，较低烯基基团，较低炔基团，芳基，杂芳基，卤代较低烷基基团，较低烷氧基较低烷基基团，较低烷氧基团，较低烯氧基团，苯氧基团或较低烷硫基团，或其药学上可接受的酸盐，可用作苯二氮卓啉受体激动剂。
• Trimethylaluminium mediated amide bond formation in a continuous flow microreactor as key to the synthesis of rimonabant and efaproxiral
  作者：Tomas Gustafsson、Fritiof Pontén、Peter H. Seeberger

  DOI：10.1039/b719603b

  日期：——

  A safe, functional-group-tolerant and high-throughput version of the trimethylaluminium mediated amide bond formation reaction has been developed in a microreactor system; rimonabant and efaproxiral were prepared to illustrate the utility of the method.

  在微反应器系统中，开发了一种安全、官能团耐受性强且高通量的三甲基铝介导的酰胺键形成反应版本；以利莫那班和依法罗西拉为例，展示了该方法的应用效果。
• Process for the preparation of alkyl 1-methylcyclopropanecarboxylate
  申请人：——

  公开号：US20020016493A1

  公开（公告）日：2002-02-07

  Disclosed is a 4-step process for the preparation of alkyl esters of 1-methylcyclopropanecarboxylic acid which comprises the steps of (1) converting &ggr;-butyrolactone to &agr;-methyl-&ggr;-butyrolactone; (2) converting the &agr;-methyl-&ggr;-butyrolactone from step (1) to an alkyl 4-halo-2-methylbutyrate; (3) producing a xylene solution of the alkyl 4-halo-2-methylbutyrate; and (4) contacting the xylene solution of an alkyl 4-halo-2-methylbutyrate from step (3) with an alkali metal alkoxide under conditions of temperature and pressure which causes vaporization of (i) an alkanol as it is formed and (ii) an alkyl 1-methylcyclopropanecarboxylate as it is formed from the alkyl 4-halo-2-methylbutyrate. Also disclosed are processes whereby the alkyl 1-methylcyclopropanecarboxylate, prepared as described above, is converted to 1-methylcyclopropylamine.

  揭示了一种制备1-甲基环丙烷羧酸烷基酯的4步过程，包括以下步骤：(1) 将γ-丁内酯转化为α-甲基-γ-丁内酯；(2) 将步骤(1)中的α-甲基-γ-丁内酯转化为烷基4-卤代-2-甲基丁酸酯；(3) 生成烷基4-卤代-2-甲基丁酸酯的二甲苯溶液；以及(4) 将步骤(3)中的烷基4-卤代-2-甲基丁酸酯的二甲苯溶液与一种碱金属烷氧化物接触，在温度和压力条件下造成（i）烷醇的汽化，因为它形成，以及（ii）从烷基4-卤代-2-甲基丁酸酯形成的烷基1-甲基环丙烷羧酸酯的汽化。还揭示了一种过程，其中根据上述描述制备的烷基1-甲基环丙烷羧酸酯被转化为1-甲基环丙基胺。
• Discovery of Novel, Orally Bioavailable β-Amino Acid Azaindole Inhibitors of Influenza PB2
  作者：Luc J. Farmer、Michael P. Clark、Michael J. Boyd、Emanuele Perola、Steven M. Jones、Alice Tsai、Marc D. Jacobs、Upul K. Bandarage、Mark W. Ledeboer、Tiansheng Wang、Hongbo Deng、Brian Ledford、Wenxin Gu、John P. Duffy、Randy S. Bethiel、Dean Shannon、Randal A. Byrn、Joshua R. Leeman、Rene Rijnbrand、Hamilton B. Bennett、Colleen O’Brien、Christine Memmott、Kwame Nti-Addae、Youssef L. Bennani、Paul S. Charifson

  DOI：10.1021/acsmedchemlett.6b00486

  日期：2017.2.9

  In our efforts to develop novel small-molecule inhibitors for the treatment of influenza, we utilized molecular modeling and the X-ray crystal structure of the PB2 subunit of the influenza polymerase to optimize a series of acyclic β-amino acid inhibitors, highlighted by compound 4. Compound 4 showed good oral exposure in both rat and mouse. More importantly, it showed strong potency versus multiple

  在努力开发新型小分子抑制剂来治疗流感的过程中，我们利用分子模型和流感聚合酶PB2亚基的X射线晶体结构优化了一系列无环β-氨基酸抑制剂，以化合物突出显示4.化合物4在大鼠和小鼠中均表现出良好的口服暴露。更重要的是，与多种A型流感病毒株（包括大流行的2009 H1N1和禽类H5N1病毒株）相比，它显示出强大的效力，即使在感染后48小时开始治疗，其在小鼠流感模型中也显示出强大的功效。化合物4具有良好的口服生物利用度，具有治疗大流行性流感和季节性流感的巨大潜力。
• Imidazoquinazoline compounds and their use
  申请人：Novo Nordisk A/S

  公开号：US05371080A1

  公开（公告）日：1994-12-06

  Imidazoquinazoline compounds having the formula ##STR1## wherein Q is ##STR2## --COOR.sup.8 or --CN; wherein R.sup.1 is H, alkyl, unsubstituted or substituted cycloalkyl, alkoxy, alkoxyalkyl or CF.sub.3 ; R.sup.8 is alkyl; R.sup.2 and R.sup.3 independently are H, alkyl optionally substituted, hydroxyalkyl, alkoxy, alkoxyalkyl, alkoxycarbonylalkyl, formylalkyl, or an acetal thereof, or R.sup.2 and R.sup.3 together with the N-atom form a 4-6 membered monocyclic amino group in which ring system one or more of the carbon atoms may be exchanged with N, O or S, sulphinyl, sulphonyl or carbonyl or an acetal thereof, each of these ring systems optionally being substituted; R.sup.4, R.sup.5, R.sup.6 and R.sup.7 independently are H, OH, halogen, CF.sub.3, NO.sub.2, NH.sub.2, CN, alkyl, alkenyl, alkynyl, alkoxy, alkoxyalkyl or alkoxycarbonyl. The compounds are useful in psychopharmaceutical preparations as anticonvulsants, anxiolytics, hypnotics, antipsychotics, antiemetics, in improving the cognitive function of the brain of mammals, or as benzodiazepine antagonists.

  咪唑喹噁啉类化合物具有以下结构式##STR1##其中Q为##STR2##--COOR.sup.8或--CN；其中R.sup.1为H，烷基，未取代或取代的环烷基，烷氧基，烷氧基烷基或CF.sub.3；R.sup.8为烷基；R.sup.2和R.sup.3独立地为H，烷基（可选地取代），羟基烷基，烷氧基，烷氧基烷基，烷氧基羰基烷基，甲酰基烷基，或其缩醛，或R.sup.2和R.sup.3与N原子一起形成一个4-6成员的单环氨基团，其中环系统中的一个或多个碳原子可与N、O或S交换，亚砜基，磺酰基或羰基或其缩醛，每个环系统可选地被取代；R.sup.4、R.sup.5、R.sup.6和R.sup.7独立地为H，OH，卤素，CF.sub.3，NO.sub.2，NH.sub.2，CN，烷基，烯基，炔基，烷氧基，烷氧基烷基或烷氧基羰基。这些化合物在精神药物制剂中作为抗癫痫药、抗焦虑药、催眠药、抗精神病药、止吐药中有用，可改善哺乳动物大脑的认知功能，或作为苯二氮䓬类拮抗剂。